Long non-coding RNA XIST regulates hyperglycemia-associated apoptosis and migration in human retinal pigment epithelial cells

Dong, Yi; Wan, Guangming; Peng, Guang-Hua; Yan, Panshi; Cheng, Qian; Li, Fuzhen

doi:10.1016/j.biopha.2020.109959

Cited by 33 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many kinds of human cancers, XIST is dysregulated, but it is not clear if XISTs forms a consequence of epigenetic instability or acts as essential factors during the pathogenesis of cancers. 134,135 Dong et al 136 revealed that XIST is down-regulated under HG conditions. It has protective function against HG-induced apoptosis of RECs by competitively binding with hsa-miR-21-5p.…”

Section: Other Types Of Lncrnamentioning

confidence: 99%

Research progress of lncRNAs in diabetic retinopathy

Huang

2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Diabetic retinopathy (DR), which is known as a severe complication of type 2 diabetes mellitus, can cause varying degrees of damage to visual acuity. The pathogenesis of DR is multifactorial and not fully understood. Many previous research studies have revealed that an aberrant level of some long non-coding RNAs (lncRNAs) may accelerate the development of DR. These lncRNAs are regulatory factors and research related to them is always underway. In this review, we will update several types of lncRNAs based on the previous studies which are related to the development of DR and discuss its potential mechanisms of action and connections. Generally, the review will help us know more about lncRNAs and provide directions for future research related to DR.

show abstract

Section: Other Types Of Lncrnamentioning

confidence: 99%

Research progress of lncRNAs in diabetic retinopathy

Huang

2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…et al, 2018;Li C. et al, 2018;Wang et al, 2018cWang et al, , 2019cLiu et al, 2019b;Qiu et al, 2019;Tian et al, 2019;Zhou et al, 2019e;Jiang et al, 2020;Rong et al, 2020;Xu et al, 2020 Osteosarcoma miR-21-5p, miR-193-3p, miR-195-5p, miR-137, miR-302b, miR-375-3p, miR-153 p21, NF-kB, PUMA, PDCD4, RSf1, YAP, RAP2B, AKT, mTOR, SNAl1 Wu D.P. et al, 2017;Zhang and Xia, 2017;Lv et al, 2018;Yang C. et al, 2018;Li H. et al, 2019;Sun X. et al, 2019;Wen et al, 2020 Pancreatic cancer miR-133a, miR-140, miR-124, miR-34a-5p, miR-34a, miR-141-3p, miR-429 EGFR, iASPP, YAP, EGFR, TGF-β2, ZEB1 Liang et al, 2017;Shen et al, 2019;Sun and Zhang, 2019;Zou et al, 2020 (Continued) Hu et al, 2018;Cheng Y. et al, 2019;Dong et al, 2020;Wang et al, 2020c;Zhao H. et al, 2020 Cervical cancer miR-200a, miR-140-5p, miR-889-3p Fus, ORC1, SIX1 Zhu H. et al, 2018;Chen X. et al, 2019c;Liu et al, 2020d Gastric cancer miR-101, miR-497, miR-185, miR-337 Chen D.L. et al, 2016;Zhang Q. et al, 2018;Zheng W. et al, 2020 1 protein (BRCA1) is a tumor suppressor.…”

Section: Lncrna Xist In Breast Cancermentioning

confidence: 99%

“…LncRNA Xist overexpression promotes retinoblastoma cells proliferation, migration, and invasion rates via negatively regulating lncRNA NKILA, but the causality has not been fully validated. In addition, lncRNA Xist, which indirectly interacts with miR-21-5p, miR-124, miR-101, miR-140-5p, and miR-200a-3p, and positively regulates VEGF, STAT3, ZEB1 and ZEB2, SOX4, and NRP1 expression, facilitates apoptosis, migration, EMT, proliferation, and invasion by activating signaling pathways, such as PI3K-Akt signaling pathway and MAPK-ERK signaling pathway ( Hu et al, 2018 ; Cheng Y. et al, 2019 ; Dong et al, 2020 ; Wang et al, 2020c ; Zhao H. et al, 2020 ). All in all, these studies suggested that lncRNA Xist serves a potential and promising clinical application for diagnosis, prognosis, and treatment.…”

Section: The Role Of Lncrna Xist In Cancermentioning

confidence: 99%

Biological Function of Long Non-coding RNA (LncRNA) Xist

Wang

Min

Guo

et al. 2021

Front. Cell Dev. Biol.

139

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) regulate gene expression in a variety of ways at epigenetic, chromatin remodeling, transcriptional, and translational levels. Accumulating evidence suggests that lncRNA X-inactive specific transcript (lncRNA Xist) serves as an important regulator of cell growth and development. Despites its original roles in X-chromosome dosage compensation, lncRNA Xist also participates in the development of tumor and other human diseases by functioning as a competing endogenous RNA (ceRNA). In this review, we comprehensively summarized recent progress in understanding the cellular functions of lncRNA Xist in mammalian cells and discussed current knowledge regarding the ceRNA network of lncRNA Xist in various diseases. Long non-coding RNAs (lncRNAs) are transcripts that are more than 200 nt in length and without an apparent protein-coding capacity (Furlan and Rougeulle, 2016; Maduro et al., 2016). These RNAs are believed to be transcribed by the approximately 98–99% non-coding regions of the human genome (Derrien et al., 2012; Fu, 2014; Montalbano et al., 2017; Slack and Chinnaiyan, 2019), as well as a large variety of genomic regions, such as exonic, tronic, and intergenic regions. Hence, lncRNAs are also divided into eight categories: Intergenic lncRNAs, Intronic lncRNAs, Enhancer lncRNAs, Promoter lncRNAs, Natural antisense/sense lncRNAs, Small nucleolar RNA-ended lncRNAs (sno-lncRNAs), Bidirectional lncRNAs, and non-poly(A) lncRNAs (Ma et al., 2013; Devaux et al., 2015; St Laurent et al., 2015; Chen, 2016; Quinn and Chang, 2016; Richard and Eichhorn, 2018; Connerty et al., 2020). A range of evidence has suggested that lncRNAs function as key regulators in crucial cellular functions, including proliferation, differentiation, apoptosis, migration, and invasion, by regulating the expression level of target genes via epigenomic, transcriptional, or post-transcriptional approaches (Cao et al., 2018). Moreover, lncRNAs detected in body fluids were also believed to serve as potential biomarkers for the diagnosis, prognosis, and monitoring of disease progression, and act as novel and potential drug targets for therapeutic exploitation in human disease (Jiang W. et al., 2018; Zhou et al., 2019a). Long non-coding RNA X-inactive specific transcript (lncRNA Xist) are a set of 15,000–20,000 nt sequences localized in the X chromosome inactivation center (XIC) of chromosome Xq13.2 (Brown et al., 1992; Debrand et al., 1998; Kay, 1998; Lee et al., 2013; da Rocha and Heard, 2017; Yang Z. et al., 2018; Brockdorff, 2019). Previous studies have indicated that lncRNA Xist regulate X chromosome inactivation (XCI), resulting in the inheritable silencing of one of the X-chromosomes during female cell development. Also, it serves a vital regulatory function in the whole spectrum of human disease (notably cancer) and can be used as a novel diagnostic and prognostic biomarker and as a potential therapeutic target for human disease in the clinic (Liu et al., 2018b; Deng et al., 2019; Dinescu et al., 2019; Mutzel and Schulz, 2020; Patrat et al., 2020; Wang et al., 2020a). In particular, lncRNA Xist have been demonstrated to be involved in the development of multiple types of tumors including brain tumor, Leukemia, lung cancer, breast cancer, and liver cancer, with the prominent examples outlined in Table 1. It was also believed that lncRNA Xist (Chaligne and Heard, 2014; Yang Z. et al., 2018) contributed to other diseases, such as pulmonary fibrosis, inflammation, neuropathic pain, cardiomyocyte hypertrophy, and osteoarthritis chondrocytes, and more specific details can be found in Table 2. This review summarizes the current knowledge on the regulatory mechanisms of lncRNA Xist on both chromosome dosage compensation and pathogenesis (especially cancer) processes, with a focus on the regulatory network of lncRNA Xist in human disease.

show abstract

“…Consequently, HDL-induced changes in miR-21-5p expression noted in the microchip array were confirmed by Q-PCR (Figure 5A): using this methodology, an increase due to HDL (63%; p < 0.05), but not apoA-I, was noted. Treatment The elevation of hsa-miR-21-5p in 1.1B4 cells detected by microchip analyses was of particular interest as this sequence and it targets have been associated with increased proliferation and reduced apoptosis [42][43][44][45][46], beta cell number and function [47][48][49] and the aetiology of diabetes [50][51][52][53][54]. Consequently, HDL-induced changes in miR-21-5p expression noted in the microchip array were confirmed by Q-PCR (Figure 5A): using this methodology, an increase due to HDL (63%; p < 0.05), but not apoA-I, was noted.…”

Section: Figurementioning

confidence: 99%

Protection against Glucolipotoxicity by High Density Lipoprotein in Human PANC-1 Hybrid 1.1B4 Pancreatic Beta Cells: The Role of microRNA

Tarlton

Lightbody

Patterson

et al. 2021

Biology

View full text Add to dashboard Cite

High-density lipoproteins provide protection against the damaging effects of glucolipotoxicity in beta cells, a factor which sustains insulin secretion and staves off onset of type 2 diabetes mellitus. This study examines epigenetic changes in small non-coding microRNA sequences induced by high density lipoproteins in a human hybrid beta cell model, and tests the impact of delivery of a single sequence in protecting against glucolipotoxicity. Human PANC-1.1B4 cells were used to establish Bmax and Kd for [3H]cholesterol efflux to high density lipoprotein, and minimum concentrations required to protect cell viability and reduce apoptosis to 30mM glucose and 0.25 mM palmitic acid. Microchip array identified the microRNA signature associated with high density lipoprotein treatment, and one sequence, hsa-miR-21-5p, modulated via delivery of a mimic and inhibitor. The results confirm that low concentrations of high-density lipoprotein can protect against glucolipotoxicity, and report the global microRNA profile associated with this lipoprotein; delivery of miR-21-5p mimic altered gene targets, similar to high density lipoprotein, but could not provide sufficient protection against glucolipotoxicity. We conclude that the complex profile of microRNA changes due to HDL treatment may be difficult to replicate using a single microRNA, findings which may inform current drug strategies focused on this approach.

show abstract

Long non-coding RNA XIST regulates hyperglycemia-associated apoptosis and migration in human retinal pigment epithelial cells

Cited by 33 publications

References 22 publications

Research progress of lncRNAs in diabetic retinopathy

Research progress of lncRNAs in diabetic retinopathy

Biological Function of Long Non-coding RNA (LncRNA) Xist

Protection against Glucolipotoxicity by High Density Lipoprotein in Human PANC-1 Hybrid 1.1B4 Pancreatic Beta Cells: The Role of microRNA

Contact Info

Product

Resources

About